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Background and objective: The purpose of asthma management is to achieve a total asthma control that
involves current control and future risk. It has proven efficacy in reducing asthma exacerbations, but the effect size
of zafirlukast for asthma exacerbations of various severity is not systematically explored.
Methods: Randomized controlled trials were searched in PubMed Central, Web of Science, and Embase, where
zafirlukast prevented asthma exacerbations in adults. The primary outcome was asthma exacerbations, the
secondary outcomes were asthma exacerbations requiring systemic corticosteroids and emergency visits,
respectively. Odds ratio (OR) with 95% confidence intervals (CI) were pooled.
Results: Twelve trials were identified. As first-line therapy, compared to those having placebo, the patients with
chronic asthma receiving zafirlukast experienced statistically lower asthma exacerbations (OR = 0.68, 95% CI = [0.45,
1.00]), but it was not found that zafirlukast was superior to placebo in asthma exacerbations requiring systemic
corticosteroids (OR = 0.76, 95% CI = [0.45, 1.29]). Furthermore, zafirlukast was inferior to ICs in asthma exacerbations
(OR = 2.11, 95% CI = [1.35, 3.30]) and requiring systemic corticosteroids (OR = 3.71, 95% CI = [1.82, 7.59]). As add-on
therapy, zafirlukast was not superior to placebo in asthma exacerbations (OR =0.99, 95% CI = [0.54, 1.81] and
requiring emergency visits (OR = 0.72, 95% CI = [0.18, 2.99]). Intriguingly, there was not a significant difference in
asthma exacerbations between zafirlukast and ICs (OR = 1.12, 95% CI = [0.53, 2.34]).
Conclusions: Our study suggests that zafirlukast, as the first-line therapy, significantly reduces mild to moderate but
not severe asthma exacerbations. In the add-on regimen, zafirlukast could not reduce asthma exacerbations, which
would perhaps result from small sample size and needs to be further studied.
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Asthma is a chronic inflammatory disorder of airways
closely associated with airway hyperresponsiveness. It is
estimated that around 300 million people suffer from
asthma and the burden of this disease to governments,
health care systems, families, and patients is increasing
worldwide [1,2]. Despite advances in knowledge of the
pathophysiology of asthma and availability of effective
therapy, currently asthma cannot be cured yet.* Correspondence: wcums-respiration@hotmail.com
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unless otherwise stated.The goal of asthma treatment is to achieve and main-
tain asthma optimal control, which includes current
control and long-term components referred to as “risk”
or “future risk” since 2009 [3]. Asthma control is evalu-
ated by a global assessment of asthma symptoms, re-
liever medicine use, lung function, and the frequency/
severity of exacerbations. It is disappointing that only 2%
of asthma patients are considered controlled across eight
Asia-Pacific countries and Hong Kong in real world set-
tings when control is assessed using the Global Initiative
for Asthma (GINA) classification [4]. Asthma exacerba-
tions, as the most important future risk, are recognized as
a common clinical manifestation in patients with severe
asthma, and are known to increase the risk of asthmatd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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exacerbations has been identified as an important com-
ponent of establishing ideal asthma control in all asthma
treatment guidelines. Inhaled corticosteroids (ICs) and
combination of ICs/long-acting β2-agonists (LABA) are
the mainstay of therapy for reducing asthma exacerbations
including the severe ones, but some patients require add-
itional treatment or prefer not to use ICs. In such patients,
leukotriene receptor antagonist (LTRA), is a promising al-
ternative to ICs therapy.
Although LTRA has been proven to be effective in im-
proving asthma control in clinical practice, few studies
systematically focused on effects of LTRA on future
asthma outcomes, such as exacerbations and their vari-
ous types. Furthermore, the relative effect size of LTRAs
for prevention of future risk of asthma exacerbations
remains unclear. Also because there is a great hetero-
geneity in pooled data of different types of LTRA, such
as montelukast, zafirlukast, panlukastandzileuton [6].
This systematic review and meta-analysis is aimed to ex-
plore effects of zafirlukast, as first-line and add-on ther-
apy, on prevention of asthma exacerbations in adults.
Methods
Search strategy and selection criteria
We searched electronic databases including PubMed (1991
to June 2013), Embase (1992 to June 2013) and Web of
Science (1992 to June 2013) for randomized controlled
trials (RCTs) using a comprehensive search strategy in-
cluding the following keywords: “zafirlukast AND (asthma
or wheezing), Limits Activated: Randomized Controlled
Trial (RCT)”. We reviewed reference lists of all included
studies, systematic reviews and narrative reviews to iden-
tify potentially relevant citations. There was no limitation
on language or year of publication.
Trials were included if they met the following criteria:
they were randomized controlled trials comparing zafir-
lukast versus placebo or other active drugs and reporting
at least one asthma exacerbation. The trials were excluded
if the patients were hospitalized for acute asthma because
the primary outcome of this study for zafirlukast in treat-
ing asthma included hospitalization for asthma exacerba-
tion. After exclusion of duplicates, two reviewers (C.F.C.
and Y.L.) reviewed the full text of all citations with titles
and abstracts that seemed to fit the criteria of inclusion.
Irrelevant citations or not randomized controlled trials
were not reviewed in full text. The number of citations
rejected and the reasons for rejection were tracked.
Data extraction and quality assessment
We reviewed each eligible citation, and obtained the full
text of all definite of possible randomized controlled trials.
From each article we extracted details regarding authors,
year of publication, sex, sample size, sample size calculation,standard treatments, interventions as the first-line or add-
on therapies, outcomes, adverse events, and intention to
treat analysis and so on.
The methodological quality of included trials was assessed
independently by two reviewers (CFC and YL). If informa-
tion was not reported adequately, authors or sponsors of
each included trial were contacted to acquire the accuracy
of the methodology and primary data. The quality of the
methods of each trial was assessed with the Cochrane
Collaboration’s tool for assessing risk of bias [7]. Our
judgments of high, low, and unclear risk of bias were cor-
roborated by citations from trial reports, correspondence,
or summarized information from the relevant sections of
the individual study reports. Any disagreement between
reviewers was resolved by consensus or by the third re-
viewer (G.W.).
Primary and secondary outcomes
In the meta-analysis assessing the prevention of zafirlu-
kast from asthma exacerbations, the number of asthma
exacerbations was a priori specified primary outcome
so as the number of detailed different exacerbations
such as requiring systemic corticosteroids, whereas emer-
gency visits and hospitalizations were identified as second-
ary outcomes.
Statistical analysis, and assessment and evaluation of the
evidence quality
The included trials were divided into two types of ana-
lyses stratified by zafirlukast as the first-line or the add-
on therapies. The mean daily dose of ICs was converted
in “microgram (μg) of beclomethasone equivalent”. Asthma
exacerbations as dichotomous variables were reported as
odds ratio (OR).
Heterogeneity was assessed by means of the Cochran
Q method and by the test of inconsistency (I2). A ran-
dom effects model was used if the Q statistic (p < 0.1) or
I2 (> 50%) was significant, or we used a fixed effects
model. We carried out subgroup analysis to assess the
source of heterogeneity and we assessed the presence of
publication bias visually with a funnel plot. Differences
in bias risk and number needed to treat (NNT) were cal-
culated to assess clinical significance. All estimates were
reported with 95% confidence intervals (CI) and all p
were 2-tailed. The meta-analysis was performed with Stata
11.0 (Stata Corp LP, College Station, Texas), and the risk
bias of the methodological quality was assessed using
RevMan 5.1 (Cochrane Review Manager, The Cochrane
Collaboration, Oxford, UK).
The quality of the evidence related to the estimation
of benefits and disadvantages in asthma exacerbation in
adult population requiring oral/parenteral corticosteroid
or emergency visits followed the suggestions of the
GRADE Working Group (http://www.gradeworkinggroup.
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3.6 (http://ims.cochrane.org/revman/gradepro).
Results
Trials included, study characteristics and quality of
reporting
The search strategy initially yielded 313 citations. Figure 1
shows details of study identification, inclusion and ex-
clusion. Twelve unique trials with 4,398 participants which
met the inclusion criteria came into statistical analysis
[8-19]. All the trials recruited adults and adolescents. The
characteristics of the included studies are listed in Table 1.
The intervention period ranged from 4 to 48 weeks
(median: 26 weeks). There were two types of interventions
for zafirlukast, and they were first-line (n = 10) or add-on
(n = 4) treatments. The dosage of zafirlukast was adminis-
trated 20 mg twice a day, except for two trials [14,19],
where patients were treated with zafirlukast 80 mg twice
daily, or were given 5 mg, 10 mg and 20 mg twice daily,
respectively. The number of patients included in these
studies varied between 38 and 762. In included stud-
ies with chronic persistent asthma, FEV1% of predictedPotentially relevant abstracts identified and screened: searc
wheezing)
limits: ra
Citation screened for titles and abstracts(n=313)
Duplicate











Figure 1 Flow diagram of trial selection and details of study identificvalue at baseline was more than 45%. In general, rescue
β2-agonists were permitted.
All the included trials were randomized and controlled.
Table 2 shows an overview of the risk bias of each
trial. There was no conflict of interest among eligible stud-
ies. Double blinding was used in all trials. On the whole,




The primary and secondary outcomes are shown in Figure 2.
Compared to those having placebo, the patients with
chronic asthma receiving zafirlukast experienced statis-
tically lower asthma exacerbations (OR = 0.68, 95% CI =
[0.45, 1.00]). However, zafirlukast as the first-line therapy
in chronic asthma was not superior to placebo in requir-
ing systematic corticosteroids for asthma exacerbation
(OR = 0.76, 95% CI = [0.45, 1.29]). Furthermore, zafirlu-
kast was inferior to ICs in patients experiencing asthma ex-
acerbations (OR = 2.11, 95% CI = [1.35, 3.30]) and asthma
exacerbations requiring systematic corticosteroids (OR =h strategy: zafirlukast and (asthma or 
ndomized controlled trial
 publication (n=96)
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ly  abstract publication (n=2)
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Table 1 Characteristic of the included trials



















T: 33.6 ± 11.1 T: 47/29 T: Z 20 mg + IP bid IB 800 ug bid × 10D
or prednisone × 5D
if asthma worsened
> 90 ≥ 70 4 weeks 48 weeks First-line/add-on + — +
C1: 33.2 ± 9.5 C1: 48/25 C1: IB 200 ug + OP bid
C2: 32.0 ± 10.5 C2: 43/33 C2: IP + OP bid
Huang CJ
2003 [9]
T: 58.6 ± 3.0 T: 8/9 T: Z 20 mg bid IB (≥ 400 μg/day or
equivalent) + SABA
NR Moderate 2 weeks 4 weeks Add-on + — +
C: 56.9 ± 2.8 C: 7/7 C: Placebo 20 mg bid
Brabson JH
2002 [10]
T: 35 ± 16 T: 141/75 T: Z 20 mg bid Albuterol as needed ≥ 88 60-85 8 days 6 weeks First-line + + +
C: 36 ± 14 C: 134/90 C: IFP 88 ug bid
Nathan RA
2001 [11]
T: 32 T: 65/85 T: Z 20 mg bid Albuterol as needed NR 50-80 7-14 days 4 weeks First-line + — —
C: 31 C: 79/65 C: Fluticasone 88 ug bid
Busse W
2001 [12]
T: 12-75 T: NR T: Z 20 mg + IP bid Albuterol as needed,
or oral or parental
corticosteriods for AE
NR 50-80 8-14 days 12 weeks First-line/add-on + + —
C: 12-75 C: NR C1: IFP 88 ug + OP bid
C2: IP + OP bid
Kim KT
2000 [13]
T: 32.9 T: 127/89 T: Z 20 mg + IP bid Albuterol as needed 88 60- 85 1 week 6 weeks First-line + + +
C: 35.5 C: 135/86 C: IFP 88 ug bid
Virchow JCJr
2000 [14]
T: 47.4 ± 12.6 T: 85/95 T: Z 80 mg bid Beclomethasone≥
1200 ug/day or
equivalent) + SABA
T: 95 50-75 2 weeks 6 weeks Add-on + — —
C: 49.2 ± 12.9 C: 98/90 C: Placebo 80 mg bid C: 94
Bleecker ER
2000 [15]
T: 31 T: 113/107 T: Z 20 mg bid Albuterol as needed 92 50-80 8-14 days 12 weeks First-line + — —
C: 31 C: 112/119 C: IFP 88 ug bid
Busse W
1999 [16]
T: 36.9 T: 85/60 T: Z 20 mg bid Albuterol as needed NR 50-80 7-14 days 4 week First-line + — —
C: 38.6 C: 77/67 C: SX 42 ug bid
Nathan RA
1998 [17]
T: 33.2 T: 127/104 T: Z 20 mg bid SABA as needed NR 45-80 2-3 weeks 13 weeks First-line + + —
C: 32.1 C: 132/91 C: Placebo 20 mg bid
Fish JE
1997 [18]
T: > 12 T: 220/294 T: Z 20 mg bid Albuterol as needed NR > 55 7-14 days 13 weeks First-line + — —
C: > 12 C: 102/146 C: Placebo 20 mg bid
Spector SL
1994 [19]
T: Z1: 37, Z2: 35,
Z3: 36, C: 36
T: Z1: 18/52, Z2: 23/45,
Z3: 18/50, C: 20/50
T: Z1: 20 mg bid,
Z2: 10 mg bid, Z3: 5 mg
bid, C: Placebo bid
Albuterol as needed NR 40-75 2 weeks 6 weeks First-line + — —
AE, asthma exacerbations; AEE, asthma exacerbation require emergency visits; AES, asthma exacerbation require systematic corticosteroid; bid, twice daily; C, control group; D, days; F, female; IB, inhalation budesonide;
IFP, inhalied fluticasone propionate; IP, inhalation of placebo; M, male; NR, not reported; OP, oral placebo; SABA, short β2 agonist; SD, standard deviation; SX, Salmeterolxinafoate; T, treatment group; y, year;







































Boushey 2005 [8] Yes Yes Yes Double-blind Yes Unclear Unclear No Yes 0.90 No
Huang 2003 [9] Yes Yes No Double-blind Yes Unclear Unclear No No NA No
Brabson 2002 [10] Yes Yes Yes Double-blind Yes Unclear Unclear Yes Yes 0.80 No
Nathan 2001 [11] Yes Yes Yes Double-blind Yes Unclear Unclear No Yes 0.80 No
Busse 2001 [12] Yes Yes No Double-blind Yes Unclear Unclear No Yes 0.80 No
Kim 2000 [13] Yes Yes No Double-blind Yes Unclear No Yes Yes 0.80 No
Virchow 2000 [14] Yes Yes Yes Double-blind Yes Unclear Unclear No No NA No
Bleecker 2000 [15] Yes Yes Yes Double-blind Yes Unclear No Yes Yes 0.80 No
Busse 1999 [16] Yes Yes Yes Double-blind Yes Unclear Unclear Yes Yes 0.80 No
Nathan 1998 [17] Yes Yes Yes Double-blind Yes Unclear Unclear No Yes 0.90 No
Fish 1997 [18] Yes Yes Yes Double-blind Yes Unclear Unclear No Yes 0.90 No






















Figure 2 Pooled odds ratio of patients experiencing different types of asthma exacerbations, comparing controlled drugs with zafirlukast.
Trials stratified according to controlled treatments (ICs and placebo) and intervention types. OR, odds ratio.
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http://www.mrmjournal.com/content/9/1/303.71, 95% CI = [1.82, 7.59]) but not in those requiring emer-
gency visits (OR = 1.07, 95% CI = [0.46, 2.51]).
In placebo-controlled studies, only two trials which had
met the inclusion criteria about patients requiring system-
atic corticosteroids for asthma exacerbations came into
meta-analysis, so we could not perform subgroup and
sensitivity analysis. Our subgroup and sensitivity ana-
lysis in ICs-controlled studies indicated that long-term
ICs with more than 12 weeks did not get much more
benefit in emergency visits in comparison to that with less
than 12 weeks (OR = 2.56, 95% CI = [0.80, 8.20] vs. OR =
1.07, 95% CI = [0.46, 2.51]).
Add-on therapy
When zafirlukast was taken as an add-on therapy, we un-
expectedly found it was not superior to placebo in asthma
exacerbations (OR =0.99, 95% CI = [0.54, 1.81] and emer-
gency visits (OR = 0.72, 95% CI = [0.18, 2.99]). Intriguingly,
there was not a significant difference in asthma exac-
erbations between zafirlukast and ICs (OR = 1.12, 95%
CI = [0.53, 2.34].
Assessment and recommendation of zafirlukast for
prevention of asthma exacerbations
The details are shown in Table 3. We assessed the asthma
exacerbations and the participants who required emer-
gency visits or needed systemic corticosteroids because
of asthma exacerbations. According to the method-
ology of each trial, the quality of evidence of zafirlukast
as first-line treatment compared with placebo, first-line/add-on treatment compared with ICs was of low or mod-
erate quality. The trials failed to undertake intention-
to-treat analysis and publication of bias in the funnel
plot among the trials contributed to decrease the quality
of evidence.
Discussion
According to GINA report, the goal of asthma manage-
ment is to achieve and maintain optimal asthma control
[2]. Recently, the concept of asthma control has been
extended to include an assessment of future risk in addition
to the previous focus on the current impairment from
asthma [20,21]. Despite advances in knowledge of the
pathophysiology of asthma and via availability of ef-
fective therapy, asthma cannot currently be cured yet.
As the most important factors in future risk of asthma,
asthma exacerbations are common in asthmatic pa-
tients’ life, and constitute a major burden on health care
resources. In patients with chronic mild to moderate
asthma, zafirlukast significantly reduced asthma exac-
erbations in the first-line regimen when compared to
placebo, but we did not find that zafirlukast was su-
perior to placebo in asthma exacerbations in add-on
regimen. Furthermore, zafirlukast was inferior to ICs
in reducing asthma exacerbations and asthma exacer-
bations requiring systemic corticosteroids. It suggested
that there was no absolute advantage from zafirlukast
in relieving severe asthma attack such as asthma exacer-
bations requiring systemic corticosteroids or emergency
visits.
Table 3 Assessment of benefits and disadvantages in asthma exacerbation
Clinical outcomes Comparisons Therapy
type










Asthma exacerbation Zafirlukast vs. placebo First-line 92/1000 62/1000
(44 to 92)
OR = 0.68 [0.45, 1.00] 1,255 (n = 4) ⊕⊕⊝⊝ Low1
Zafirlukast vs. ICs First-line 31/1000 64/1000
(42 to 96)
OR = 2.11 [1.35, 3.30] 1,963 (n = 6) ⊕⊕⊕⊝ Moderate2
Zafirlukast vs. ICs Add-on 83/1000 92/1000
(46 to 175)
OR = 1.12 [0.53, 2.34] 353 (n = 2) ⊕⊕⊝⊝ Low3
Zafirlukast vs. placebo Add-on 121/1000 120/1000
(69 to 200)




Zafirlukast vs. placebo First-line 108/1000 86/1000
(40 to 186)
OR = 0.76 [0.45, 1.29] 544 (n = 2) ⊕⊕⊝⊝ Low5
Zafirlukast vs. ICs First-line 18/1000 64/1000
(32 to 123)




Zafirlukast vs. ICs First-line 22/1000 23/1000
(10 to 53)
OR = 1.07 [0.46, 2.51] 994 (n = 3) ⊕⊕⊝⊝ Low7
Zafirlukast vs. placebo Add-on 60/1000 44/1000
(11 to 159)
OR = 0.72 [0.18, 2.99] 163 (n = 3) ⊕⊕⊝⊝ Low8
CI,= confidence intervals; ICs,= inhaled corticosteroids; OR, odds ratio.
1 (−1 limitations) (−1 publication bias). Four trials (Boushey HA 2005, Busse W 2001, Fish JE 1997, Nathan RA 1998) have high quality, but all of them fail to adhere
to an intention-to-treat analysis, so suggesting high likelihood of bias (−1 of quality). Four trials were included, from the funnel plot we strongly suspected there
was publication bias.
2 (−1 limitations). Busse W 2001 and Nathan RA 1998 fail to adhere to an intention-to-treat analysis, so suggesting high likelihood of bias (−1 of quality).
3 (−1 limitations) (−1 publication bias). Busse W 2001 and Boushey HA 2005 fail to adhere to an intention-to-treat analysis, so suggesting high likelihood of bias
(−1 of quality). Only two trials were included, from the funnel plot we strongly suspected there was publication bias.
4 (−1 limitations) (−1 publication bias). Three trials (Boushey HA 2005, Busse W 2001, Huang CJ 2003) have high quality, but all of them fail to adhere to an
intention-to-treat analysis, so suggesting high likelihood of bias (−1 of quality). Three trials were included, from the funnel plot we strongly suspected there was
publication bias.
5 (−1 limitations) (−1 publication bias).Busse W 2001 and Nathan RA 1998 fail to adhere to an intention-to-treat analysis, so suggesting high likelihood of bias
(−1 of quality). Only two trials were included, from the funnel plot we strongly suspected there was publication bias.
6 (−1 limitations) (−1 publication bias) (+1 large effect). Busse W 2001 fails to adhere to an intention-to-treat analysis, so suggesting high likelihood of bias (−1 of
quality). Three trials were included, from the funnel plot we strongly suspected there was publication bias. Large effect (M-H pooled OR = 3.712) in the absence of
other methodological limitations), so upgrading quality of evidence.
7 (−1 limitations) (−1 publication bias).Boushey HA 2005 fails to adhere to an intention-to-treat analysis, so suggesting high likelihood of bias (−1 of quality). Trials
were included, from the funnel plot we strongly suspected there was publication bias.
8 (−1 limitations) (−1 publication bias).Boushey HA 2005 and Huang CJ 2003 fail to adhere to an intention-to-treat analysis, so suggesting high likelihood of bias
(−1 of quality). Trials were included from the funnel plot we strongly suspected there was publication bias.
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in asthma therapy. Zafirlukast showed an overall beneficial
effect on the symptoms of chronic asthma as measured by
asthma exacerbations and other parameters when com-
pared to placebo. Though there is a less-stringent defin-
ition for asthma exacerbation (based on patient’s current
therapy change, oral or inhaled steroids use, worsening
symptoms, emergency room treatment or hospitalization,
or rescue albuterol use), definitions of a mild or moderate
asthma exacerbation are justifiable according to a recently
published ATS/ERS statement [20]. On the basis of ATS/
ERS, severe asthma exacerbations can be defined as events
that require urgent action on the part of the patient and
physician to prevent a serious outcome, such as use
of systemic corticosteroids, hospitalization or death from
asthma; moderate exacerbations as events that result in a
temporary change in treatment, in an effort to prevent the
exacerbation from becoming severe; and mild exacer-
bations that are only just outside the normal range of
variation in symptoms or changes in flow rates for theindividual patient and may reflect transient loss of asthma
control. In our study, the available data demonstrated
that zafirlukast only decreased the risk of mild and mod-
erate asthma exacerbations, but not severe asthma exacer-
bations, such as requiring systemic corticosteroids and
emergency visits in chronic persistent asthma. Although
zafirlukast was superior to placebo in reducing the risk of
asthma exacerbations, our results indicated that patients
receiving low-dose ICs from 352 to 400 ug daily had fairly
fewer asthma exacerbations than those taking zafirlukast.
It was consistent with Ducharme FM’s results that, in
adults with mild to moderate chronic asthma, the risk of
exacerbations requiring systemic glucocorticoids was 60%
higher with daily oral leukotriene receptor antagonists
than with doses of ICs equivalent to 400 ug/day inhaled
beclometasone [6].
ICs were considered as the first-line treatment for pa-
tients with moderate to severe persistent asthma, but some
patients require additional treatments or prefer not to use
ICs. Our study manifested that the addition of zafirlukast
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ture risk of asthma outcomes. It indicated that zafirlu-
kast, as an add-on therapy, might be possibly associated
with improving asthma symptoms but not asthma ex-
acerbations in future. Reid et al. found that zafirlukast
significantly improved FEV1 and PEF, and reduced morn-
ing waking with asthma and β2-agonist puffs [22]. In bron-
chial challenge studies, zafirlukast attenuated the lower
airway symptoms and pulmonary response to cat chal-
lenge [23,24]. Asthma is a complex multifactorial disorder
involving a variety of different mechanisms. Environmen-
tal exposure and genetic background play a major role in
development of asthma and triggering asthma symptoms.
Genetic studies have produced heterogeneous results with
little replication. More than 100 genes had been reported
in connection to asthma or asthma phenotypes since the
first study linking a genetic locus to asthma in 1989 [25].
Our recent study systemically explored the network of
asthma-related genes where three hundred and twenty-six
genes were identified [26]. The poor asthma control is
related to deteriorative airway inflammation, asthma-related
comorbidities such as obesity, rhinitis, gastroesophageal
reflux disease, obstructive sleep apnoea, and exacerba-
tion risk which is an important component to investi-
gate asthma control [27].
In our systematic review, 10 out of twelve trials defin-
itely described subjects characterized by no smoking, but
there was not enough information to identify the status of
smoking in other two trials [10,11]. Active smoking is as-
sociated with an increased morbidity from asthma and im-
pairs the response to ICs [28,29]. The children exposed to
environmental tobacco smoking had impaired recovery
after hospitalization for acute asthma [30]. Extensive stud-
ies reveal that diet, particularly breast-feeding, is related
to the development of asthma. Atopy is an independent
risk factor of occupational asthma [31]. Body mass index
(BMI) is an important independent predictor of asthma
development and poor asthma control and asthma out-
come [31], but we did not perform the subgroup analysis
because only one trial provided the information on BMI
[8]. More available data are needed to reveal the effect of
zafirlukast on asthma exacerbations in patients with dif-
ferent BMI. Compared to normal weight asthmatics, the
obese children are more likely to have severe disease and
airflow obstruction [32].
There are sorts of inflammatory cells and mediators re-
lated to asthma mechanisms. An important role in airways
inflammation is played by cysteinylleukotrienes, which are
powerful agents inducing bronchoconstriction, mucus hy-
persecretion and airways hyperresponsiveness, and act as
chemoattractants for eosinophils in the airways [33]. In pa-
tients with mild to moderate persistent asthma, zafirlukast,
one of leukotriene receptor antagonists, produced rapid
improvement in pulmonary function and daytime asthmasymptoms, meanwhile decreasing the need for rescue ther-
apy with β2-agonist and improving asthma control when
combined with ICs [34]. Unexpectedly, we did not find
that zafirlukast was superior to placebo in asthma ex-
acerbations and emergency visits in either the first-line
and add-on therapies. Furthermore, we did not find differ-
ence in asthma exacerbations between zafirlukast and ICs
in add-on regimens. However, because of small sample
size, it does not seem completely believable that zafirlu-
kast was not superior to placebo in asthma exacerbations
requiring systemic corticosteroids, and there was no signifi-
cant difference in emergency visits for asthma exacerba-
tions between zafirlukast and ICs in the first-line regimen.
Additionally, all results from comparisons between zafirlu-
kast, ICs and placebo in the add-on regimens were also
somewhat unreliable for a low power. This suggests that
more randomized controlled trials or larger sample size
are needed to identify these difference among zafirlukast,
ICs and placebo.
Our study has some limitations. First, the small number
of trials could have lowered the power and lead to relative
wide confidence intervals also precluding meta-regression
analysis although high quality randomized controlled trials
were included. Second, as it is well known, smoking, obes-
ity, allergen, adherence and age are factors modifying the
response to antiasthma medications, but this information
was not available to be further analyzed.
Conclusions
This systematic review included 12 randomized controlled
trials to assess the efficiency of zafirlukast in preventing
asthma exacerbations as future risk in chronic persistent
mild to moderate asthma. Our results showed that zafirlu-
kast could decrease risk of mild and moderate but not se-
vere exacerbations as the first-line regimen. Furthermore,
it was evidently inferior to ICs in any kinds of exacerba-
tions. Because it has not enough available information to
support subgroup and sensitivity analysis, more trials are
needed to confirm these conclusions that would benefit
the asthma patients in clinical practice.
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